Bacteria are quickly becoming resistant to known antibiotics, and few new drugs are being developed to fill the void, experts say. Antibiotics are not as profitable for drugmakers as drugs to treat chronic diseases, so the federal government should develop a system to reward discovery and development of new antibiotics, says infectious disease specialist Jeffrey Jacobson.

Related Summaries